Baking Soda kills Cancer

Baking Soda kills Cancer

Baking Soda kills Cancer

Even the most aggressive cancers which have metastasized have been reversed with baking soda cancer treatments. Although chemotherapy is toxic to all cells, it represents the only measure that oncologists employ in their practice to almost all cancer patients.

In fact, 9 out of 10 cancer patients agree to chemotherapy first without investigating other less invasive options.

Doctors and pharmaceutical companies make money from it. That’s the only reason chemotherapy is still used. Not because it’s effective, decreases morbidity, mortality or diminishes any specific cancer rates. In fact, it does the opposite. Chemotherapy boosts cancer growth and long-term mortality rates and oncologists know it.

A few years ago, University of Arizona Cancer Center member Dr. Mark Pagel received a $2 million grant from the National Institutes of Health to study the effectiveness of personalized baking soda cancer treatment for breast cancer.

Obviously, there are people in the know who have understood that sodium bicarbonate, that same stuff that can save a person’s life in the emergency room in a heartbeat, is a primary cancer treatment option of the safest and most effective kind.

Studies have shown that dietary measures to boost bicarbonate levels can increase the pH of acidic tumors without upsetting the pH of the blood and healthy tissues. Animal models of human breast cancer show that oral sodium bicarbonate does indeed make tumors more alkaline and inhibit metastasis.

Based on these studies, plus the fact that baking soda is safe and well tolerated, world renowned doctors such as Dr. Julian Whitaker have adopted successful cancer treatment protocols as part of an overall nutritional and immune support program for patients who are dealing with the disease.

The Whitaker protocol uses 12 g (2 rounded teaspoons) of baking soda mixed in 2 cups water, along with a low-cal sweetener of your choice. (It’s quite salty tasting.)

Sip this mixture over the course of an hour or two and repeat for a total of three times a day. One man claims he has found a cure for cancer using baking soda and molasses and actually successfully treated his own disease by using baking soda.

When taken orally with water, especially water with high magnesium content, and when used transdermally in medicinal baths, sodium bicarbonate becomes a first-line medicinal for the treatment of cancer, and also kidney disease, diabetes, influenza and even the common cold.

It is also a powerful buffer against radiation exposure, so everyone should be up to speed on its use. Everybody’s physiology is under heavy nuclear attack from strong radioactive winds that are circling the northern hemisphere.

Dr. Robert J. Gillies and his colleagues have already demonstrated that pre-treatment of mice with baking soda results in the alkalinization of the area around tumors. The same researchers reported that bicarbonate increases tumor pH and also inhibits spontaneous metastases in mice with breast cancer.

The Baking Soda Formula for Cancer

To make the baking soda natural cancer remedy at home, you need:

  • maple syrup,
  • molasses or
  • honey
  • to go along with the baking soda.

In Dr. Sircus’ book, he documented how one patient used baking soda and blackstrap molasses to fight the prostate cancer that had metastasized to his bones. On the first day, the patient mixed 1 teaspoon of baking soda with 1 teaspoon of molasses in a cup of water.

He took this for another 3 days after which his saliva pH read 7.0 and his urine pH read 7.5.

Encouraged by these results, the patient took the solution 2 times on day 5 instead of once daily. And from day 6 – 10, he took 2 teaspoons each of baking soda and molasses twice daily.

By the 10th day, the patient’s pH had risen to 8.5 and the only side effects experienced were headaches and night sweat (similar to cesium therapy).

The next day, the patient had a bone scan and too other medical tests. His results showed that his PSA (prostate-specific antigen, the protein used to determine the severity of prostate enlargement and prostate cancer) level was down from 22.3 at the point of diagnosis to 0.1.

Another baking soda formula recommends mixing 90 teaspoons of maple syrup with 30 teaspoons of baking soda.

To do this, the maple syrup must be heated to become less viscous. Then the baking syrup is added and stirred for 5 minutes until it is fully dissolved.

This preparation should provide about 10-day worth of the baking soda remedy. 5 – 7 teaspoons per day is the recommended dose for cancer patients.

Care should be taken when using the baking soda remedy to treat cancer. This is because sustaining a high pH level can itself cause metabolic alkalosis and electrolyte imbalance. These can result in edema and also affect the heart and blood pressure.

One does not have to be a doctor to practice pH medicine. Every practitioner of the healing arts and every mother and father needs to understand how to use sodium bicarbonate.

Bicarbonate deficiency is a real problem that deepens with age so it really does pay to understand and appreciate what baking soda is all about.

Do you have baking soda in your house?



Doctors Test Tumor Paint

Doctors Test Tumor Paint

Doctors Test Tumor Paint

Eighteen months ago, Shots first told readers about tumor paint, an experimental substance derived from scorpion venom. Inject tumor paint into a patient’s vein, and it will actually cross the blood-brain barrier and find its way to a brain tumor. Shine near-infrared light on a tumor coated with tumor paint, and the tumor will glow.

The main architect of the tumor paint idea is a pediatric oncologist named Dr. Jim Olson. As a physician who treats kids with brain cancer, Olson knows that removing a tumor is tricky.

“The surgeons right now use their eyes and their fingers and their thumbs to distinguish cancer from normal brain,” says Olson. But poking around in someone’s brain with only those tools, it’s inevitable surgeons will sometimes miss bits of tumor or, just as bad, damage healthy brain cells.

So Olson and his colleagues at the Fred Hutchinson Cancer Center in Seattle came up with tumor paint. They handed off commercial development of the compound to Blaze Bioscience.

After initial studies in dogs showed promise, the company won approval to try tumor paint on human subjects. Those trials are taking place at the Cedars Sinai Medical Center in Los Angeles.

Dr. Chirag Patil is one of those surgeons. He says it’s remarkable that you can inject tumor paint into a vein in a patient’s arm, have it go to the brain and attach to a tumor, and only a tumor. “That’s a concept that neurosurgeons have probably been dreaming about for 50 years,” he says.

An image of a mouse brain tumor under near-infrared light. The blue-green glow in the upper right quadrant is the tumor, labeled with tumor paint.

Patil says they’ve now used tumor paint on a about a half-dozen patients with brain tumors. They use a special camera to see if the tumor is glowing.

“The first case we did was a deep tumor,” says Patil. “So with the camera, we couldn’t really shine it into this deep small cavity. But when we took that first piece out and we put it on the table. And the question was, ‘Does it glow?’ And when we saw that it glows, it was just one of those moments …’Wow, this works.’ ”

In this first study of tumor paint in humans, the goal is just to prove that it’s reaching the tumor. Future studies will see if it actually helps surgeons remove tumors and, even more important, if it results in a better outcome for the patient.

That won’t be quick or easy. Just getting to this point has been a long slog, and there are bound to be hurdles ahead.

And even if tumor paint does exactly what it’s designed to do, Dr. Keith Black, who directs neurosurgery at Cedars-Sinai, says it probably isn’t the long-term solution to brain cancer. “Because surgery is still a very crude technique,” he says.

Even in the best of circumstances, Black says, surgery is traumatic for the patients, and tracking down every last cell of a tumor is probably impossible. Plus, it’s inevitable that some healthy brain tissue will be damaged in removing the tumor.

“Ultimately, we want to eliminate the need to do surgery,” says Black. A start in that direction will be to use a compound like tumor paint to deliver not just a dye, but an anti-cancer drug directly to a tumor. That’s a goal several research groups, including Jim Olson’s, are working on.



Link for Colon Cancer Discovered

Key Link Responsible for Colon Cancer Initiation and Metastasis discovered:

Key Link Responsible for Colon Cancer Initiation and Metastasis discovered

Key Link Responsible for Colon Cancer Initiation and Metastasis discovered

CXCR2- a key genetic culprit that is implicated in the tumor formation, growth and progression in a mouse model of colon cancer has been identified by scientists.
 Key Link Responsible for Colon Cancer Initiation and Metastasis discovered

“We have been trying for the past several years to understand the precise molecular links between inflammation and cancer, said DuBois. “We have demonstrated that CXCR2 mediates a critical step in the setup of the blood circulatory machinery that feeds tumor tissue. This provides an important new clue for the development of therapeutic targets to neutralize the effect of CXCR2 on colon cancer.”

The DuBois’ Laboratory for Inflammation and Cancer, which includes lead author Hiroshi Katoh, and colleagues Dingzhi Wang, Takiko Daikoku, Haiyan Sun, and Sudhansu K. Dey, published the results in the November 11 issue of Cancer Cell.

The results provide critical new clues toward the prevention of colorectal cancer, the second leading cause of cancer deaths in the U.S. Despite the availability of colonoscopy screening, the 5-year survival rate remains low, due to a large number patients presenting with advanced stages of the disease. Currently, there are no clinically available blood tests for the early detection of sporadic colon cancer.

Inflammation has long been associated with increasing one’s risk for colon cancer. For instance, more than 20 percent of patients with a form of inflammatory bowel disease (IBD) develop colorectal cancer within 30 years of diagnosis. This colitis-associated cancer has a slow progression, but a very poor response to treatment and a high mortality rate.

Researchers have known that the broad mechanisms of cancer involve an interplay with the immune system response that includes: recruiting immune cells that influence the tumor microenvironment, escaping from host immunosurveillance and suppression, shifting of the host immune response, and tumor-associated angiogenesis to establish the blood supply.

For the study, the research team first “knocked-out” or removed the CXCR2 gene in mice, and found that the signs typically associated with inflammation were prevented. Furthermore, they demonstrated that CXCR2 dramatically suppressed colonic inflammation and the colitis associated tumor formation, growth and progression in mice.

CXCR2 decorates the outer part of immune cells called myeloid-derived suppressor cells, or MDSCs, that work to block the immune response of killer CD8+ T cells. In the knockout mice, without CXCR2 present, the MDSC cells could no longer migrate from the circulatory system to the colon, dodge the killer CD8+ T cell immune response, and feed the blood supply of the tumor environment. Furthermore, when they transplanted normal MDSC cells (with normal CXCR2) into the knockout mice, tumor formation was restored.

“These results provide the first genetic evidence that CXCR2 is required for recruitment of MDSCs into inflamed colonic mucosa and colitis-associated tumors,” said DuBois.

For DuBois, who has devoted his career to unraveling the inflammatory circuitry responsible for colon cancer, the results help connect the dots between the immune system, inflammation and tumor formation and metastasis.

DuBois’ team was the first to show that colorectal tumors contained high levels of the enzyme cyclo-oxygenase-2 (COX-2), a key step in the production of pro-inflammatory mediators such as prostaglandin E2 (PGE2). PGE2 triggers production of a CXCR2 molecule that fits into CXCR2 like a baseball into a glove’s pocket and activates it. CXCR2, like the pied piper, recruits MDSCs from the bloodstream to sites of inflammation, causing the colon cancer tumors to evade the immune killer CD8+ T immune response.

“Our findings reveal not only how MDSCs are recruited to local inflamed tissues and tumor microenvironment and how local MDSCs contribute to colorectal cancer progression, but now also provide a rationale for developing new therapeutic approaches to subvert chronic inflammation- and tumor-induced immunosuppression by using CXCR2 antagonists and neutralizing antibodies,” said DuBois.